Literature DB >> 11678793

Systemic bioavailability of fluticasone proprionate.

B J Lipworth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11678793      PMCID： PMC2014587          DOI： 10.1046/j.0306-5251.2001.01456.x-i3

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia.

Authors:  J G O'Brien; B J Dong; R L Coleman; L Gee; K B Balano
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

3.  Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

Authors:  S M Pond; D J Birkett; D N Wade
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

4.  Gliclazide hydroxylation by rat liver microsomes.

Authors:  A Rieutord; I Stupans; G M Shenfield; A S Gross
Journal:  Xenobiotica       Date:  1995-12       Impact factor: 1.908

5.  Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.

Authors:  K Komatsu; K Ito; Y Nakajima; S i Kanamitsu; S Imaoka; Y Funae; C E Green; C A Tyson; N Shimada; Y Sugiyama
Journal:  Drug Metab Dispos       Date:  2000-04       Impact factor: 3.922

6.  [Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990].

Authors:  E Girardin; T Vial; E Pham; J C Evreux
Journal:  Ann Med Interne (Paris)       Date:  1992
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.